Showing results (171-180 of 178) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 178 results.
BMC Medicine|January 12, 2012
Reversal of type 1 diabetes via islet β cell regeneration following immune modulation by cord blood-derived multipotent stem cellsYong Zhao, Zhaoshun Jiang, Tingbao Zhao, et al.
Stroke|August 1, 2013
Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trialDavid Preiss, Thomas D Giles, Laine E Thomas, et al.
BMJ Open|December 4, 2012
Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trialDavid Preiss, Laine E Thomas, Jie-Lena Sun, et al.
Autoimmunity Reviews|February 2, 2022
Stem Cell Educator therapy in type 1 diabetes: From the bench to clinical trialsYong Zhao, Colette M Knight, Zhaoshun Jiang, et al.
Circulation. Heart Failure|February 8, 2013
Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research studyYee Weng Wong, Laine Thomas, Jie-Lena Sun, et al.
Trials|October 6, 2022
Study in Parkinson's disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trialCharity G Patterson, Elizabeth Joslin, Alexandra B Gil, et al.
The New England Journal of Medicine|March 16, 2010
Effect of valsartan on the incidence of diabetes and cardiovascular events, John J McMurray, Rury R Holman, et al.
The New England Journal of Medicine|March 16, 2010
Effect of nateglinide on the incidence of diabetes and cardiovascular events, Rury R Holman, Steven M Haffner, et al.
Pageof 18